When a trial is
off-course,
we put it back
on target.
Clinical TrialRx rescues off-course clinical trials and RWE programs at every phase for pharma, biotech, and medical device sponsors. For F500 sponsors, the Build-Transfer-Exit model builds AI/ML capability your team owns within 18 months, targeting 35% clinical operations headcount efficiency.
All Phases + RWE
All Phases + RWE
Six Continents
Multi-Indication Depth
Trials Rescued
What rescue looks like when frameworks meet operators.
Results from the principal's documented record in prior roles, across 300+ protocols and 900+ projects.
Why about 80% of clinical trials miss their enrollment timelines, and what it costs sponsors.
Trial delays do not come from one failure. They compound across start-up, site activation, recruitment, and contracting, each adding months, amendment cycles, and burn. The data below maps where pharma, biotech, and device programs are losing the race.
If your trial shows two or more of these signals, it is time for an independent assessment, before drift turns into an amendment.
Miss initial enrollment targets
About 80% of clinical trials fail to meet their initial enrollment target and timeline, a benchmark repeated across the recruitment literature for a decade.
Contracts and budgets named the top fix
Of about 100 site professionals surveyed identified contract and budget support as the top area where sponsors and CROs can improve.
Contract and budget delays "frequently"
Of site respondents report experiencing contract and budget delays frequently, a recurring start-up constraint rather than a one-off negotiation issue.
Participants who stop early
In a 2025 survey of 4,415 past participants, 11% stopped before their last scheduled visit, and 21% did not report completing the full study.
Spent between trials
IQVIA reports that inter-trial intervals added 17 months to program timelines in 2025, and that they grew by a further 3 months in 2026.
Labs still digitally siloed
Of 104 biopharma R&D executives surveyed report that their R&D labs remain digitally siloed.
The two most expensive words in clinical development: protocol amendment and enrollment extension.
Amendments are one of the most common and costly sources of unplanned delay and unbudgeted expense in clinical trials, and the industry benchmark is moving in the wrong direction. The data below is why every Clinical TrialRx engagement is architected to prevent the amendment, not merely process it.
Protocols now amended
Of Phase I-IV protocols carry at least one substantial amendment, up from 57 percent in 2015. The mean number of amendments per protocol has climbed 60 percent to 3.3.
Need-to-amend to final approval
Average time from identifying the need to amend through the last oversight approval. Sites operate on divergent protocol versions for a mean of 215 days across that window.
Median cost per Phase III amendment
Median direct implementation cost of one substantial Phase III amendment ($141K at Phase II), as reported in 2016. Adjusted for inflation from 2016 alone, that floor is approximately $744K today ($196K at Phase II). No newer published cost benchmark exists, and rising protocol complexity puts the true figure higher still.
In the principal's rescue engagements, submissible RWE evidence packs and 5-Gate protocol governance cut rescue-trial amendment cycles 45 percent across oncology and rare-disease programs, because the cheapest amendment is the one the design never needed.
The data partner brings the asset. Clinical TrialRx delivers the study.
Most trial delays show up in real-world data long before they show up on a timeline. Clinical TrialRx wraps study execution around data from originated point-of-care data partners, data infrastructure and tokenization partners, and RWE analytics partners, so the protocol, the site list, and the enrollment plan are tested against real patients before they are tested against the calendar.
- Originated point-of-care data partners
- Data infrastructure and tokenization partners
- RWE analytics partners
- Protocol stress-testing and feasibility
- Site selection and enrollment
- Governance, monitoring, and data lock
- One accountable plan
- One bid, one delivery team
- Evidence built for the use it must survive
Where trials lose time, and what Clinical TrialRx does at each point.
Feasibility and protocol design
Where it breaksEligibility criteria are written for patients who are rare in practice.
What we doStress-test inclusion and exclusion criteria, visit burden, and endpoints against real-world patient data before first patient in, so the amendment is avoided rather than fixed.
Site selection
Where it breaksSites are chosen from feasibility surveys that overstate available patients.
What we doRank sites by real patient populations and historical enrollment performance, not self-reported survey answers.
Enrollment
Where it breaksShortfalls are found after the enrollment window is already lost.
What we doForecast site-level enrollment from real-world data and flag shortfalls early. Work with partners to identify likely eligible populations near active sites, using de-identified, tokenized data under each partner's privacy, consent, and IRB-approved recruitment framework.
Amendments
Where it breaks76% of protocols are amended, each cycle runs 260 days, and one Phase III amendment carries a $535K median direct cost (benchmarks above).
What we doEvery amendment avoided at design removes a cycle from the timeline. Tufts CSDD estimates a day of delay costs about $40,000 in direct Phase II and III trial cost and about $500,000 in average lost prescription sales.
Rescue
Where it breaksA late trial has no evidence of why it is late.
What we doRun the existing rescue method (VOC-7 audit, 5-Gate governance, FSP oversight) with the data partner layer alongside it, to re-forecast enrollment, re-target sites, and reset the plan on real numbers.
RWE is not a phase
Where it breaksReal-world evidence is treated as a post-market afterthought.
What we doCarry the same real-world data from feasibility through Phases I to IV and post-market, so external controls, label expansion, safety surveillance, and payer evidence draw on one consistent evidence base. See the RWE Doctrine.
The translator between the platform and the science.
Data platforms are bought for what they promise; studies are judged by what they deliver. In prior roles, the principal has taken CTMS, EDC, monitoring software, and AI/ML from purchase into live operation, including a global CTMS implementation across 21 international affiliates. In RWE leadership roles, that work extended hands-on to the underlying program data: living reviews of global registries and claims databases, and orphan-disease burden estimates built for regulatory-grade submissions.
How the partnership runs: VOC-7, BAP, and BEP.
Before the offer reaches a sponsor, diagnose which of the seven reasons sponsors say NO is already in play, so the proposal answers the objection.
Joint pursuit from Interest through Win, with the data asset and the execution plan in one bid, so the sponsor buys one accountable answer.
Define through Close, with every data commitment made in the bid carried into delivery without translation loss.
Your trial is late, or about to be.
Start with a delay rescue assessment: where the timeline is slipping, what the data shows, and the governed path back.
Schedule a Delay Rescue AssessmentYou have the data. Your sponsors need the study delivered.
Bring Clinical TrialRx in as the study execution layer for your sponsor engagements.
Partner With UsRWE is not a phase. It runs across the whole lifecycle.
Clinical TrialRx designs and delivers real-world evidence and real-world data programs across every stage of development, from the first feasibility question to post-market surveillance, so one consistent evidence base serves the protocol, the regulator, the payer, and the sponsor's commercial team.
Natural history and patient counts: is the study feasible?
Dose and safety context from real populations
Eligibility stress-tested; feasibility on real counts
Endpoints anchored; comparator context; amendment risk reduced
Label expansion; comparative effectiveness
Surveillance; payer dossiers; value-based contract evidence
- RWE study design across Phases I to IV: observational (NIS), PASS, registries, PRO, HEOR, and pragmatic Phase IV
- Systematic literature review and real-world data-lake strategy
- Submissible evidence packs for FDA, EMA, PMDA, TGA, and HSA
- RWE and RWD designs introduced to sponsors new to real-world evidence, implemented alongside their interventional programs
Scope an RWE program to the use it must survive: regulatory, safety, payer, or commercial.
Price
Bid misaligned to delivered value; change-order surprises; TCO never surfaced.
Strategy
Operational plan disconnected from sponsor's portfolio goals and regulatory strategy.
Relationships
No C-suite advocate; steering committee disengaged; PM turnover destroys continuity.
Retention
Key study staff churn mid-program; institutional knowledge walks out the door.
Communication
Late, filtered, or sanitized escalation; sponsor learns of risk at data lock, not at gate review.
Accountability
Action items with no owner; metrics reported but not governed; issues recur across studies.
Executive Knowledge
CRO senior leadership absent from critical milestones; no strategic depth on escalation.
YES Lever Activation
Each NO is re-engineered as a YES lever through our Client Delight COE: governed, measured, and owned.
Every capability a sponsor needs, under one delivery architecture.
Many sponsors buy clinical operations in slices: monitoring only, RWE only, commercial only. Clinical TrialRx delivers the full clinical operations stack, concept through post-market, so handoffs do not fail and accountability never disperses. Twelve service lines, three categories, one operator.
Category I · Trial Execution
End-to-end study delivery across every phase and design: interventional, observational, and hybrid.
Phase I First-in-Human
FIH, dose escalation, MAD/SAD, PK/PD studies. Site selection, IRB submission, safety review board orchestration, real-time safety review.
Phase II Proof of Concept
Dose-finding, signal detection, adaptive POC designs. Bayesian and frequentist analysis frameworks, biomarker integration, futility analysis.
Phase III Pivotal & Registrational
Multi-country pivotal trials at scale, including an $875M Phase III program: 10,101 patients randomized at 177 sites in 26 countries.
Phase IV Post-Market
Label expansion, safety surveillance, observational Phase IV programs. Long-term follow-up, RMP/REMS execution, signal-detection programs across multi-indication post-market portfolios.
RWE Observational & Registries
NIS, PASS, pragmatic Phase IV, PRO, disease and product registries. Methodologically rigorous designs aligned to FDA, EMA, and PMDA regulatory pathways.
RWD Strategy & Data Lakes
Real-world data-lake architecture, claims and EHR integration, systematic literature review, submissible evidence packs for orphan and rare-disease assets.
Every RWE/RWD engagement is scoped to the use it must survive, because evidence built for the wrong buyer fails review at the right one. See the RWE Doctrine: one asset, every phase.
Category II · Quality, Oversight & Rescue
The governance layer: risk-based monitoring, auditing, and trial rescue across every phase, every design. Phase I through Phase IV, plus RWE/RWD registries. No phase is too late, no design too complex.
Risk-Based Monitoring
Centralized and on-site RBM teams via FSP governance, resource allocation by site risk profile, AI/ML-driven anomaly detection, source data verification optimization.
Quality & Auditing
GCP audits, vendor and CRO audits, regulatory inspection readiness, mock FDA/EMA inspections, CAPA management, deviation root-cause analysis.
Clinical Trial Rescue, Every Phase
The headline offering. We rescue at every phase, every design, every geography. Phase I FIH safety studies that lost their PI. Phase II POCs missing enrollment by 80%. Phase III pivotals with data integrity questions. Phase IV post-marketing studies on regulatory hold. RWE/RWD registries with submissible-evidence gaps.
Category III · Commercial & Win Solutions
Win more bids. Close bigger deals. Convert sponsor NOs into YES, using the same frameworks that drove a $1B / 5-year BD initiative.
Bid Defense Solutions
Cross-functional bid defense methodology developed and chaired at a Tier-1 global central laboratory firm. Win-strategy playbook per account, C-suite advocacy, competitive positioning.
Sales & BD Strategy
First Choice global sales strategy bridging BD, Operations, PM, and Commercialization. AOP alignment, pipeline architecture, Fortune 100 sponsor engagement.
Client Delight Activation
VOC-7 diagnostic deployment, turn the seven reasons sponsors say NO into governed YES levers. Lift retention, expand wallet share, restore C-suite trust.
Five engagement tiers. Scale as far as your program needs.
The twelve service lines above can be deployed at any tier of engagement. The Service Value Added Model (SVAM) lets sponsors scale from targeted staffing augmentation through full strategic partnership, transparent upgrade paths, outcome-aligned pricing, zero bid-defense translation loss between what we promise and what we deliver.
Why SVAM exists: SVAM was developed while leading the FSP delivery practice for an operating company of the largest U.S. staffing firm (Staffing Industry Analysts, 2017), as it moved from staff augmentation to a true service-line model. The five tiers below are the path mapped then, and the path every sponsor can now follow.
Staffing
Targeted resource augmentation, senior operators embedded into your existing clinical team to unblock capacity constraints.
- Interim CPM / TPM / Ops leads
- CRA / monitoring surge
- Regulatory & submission specialists
- Rapid deploy · 2–4 wk
Limited Service
Scoped functional deliverables, discrete work packages with defined SOW, timeline, and acceptance criteria.
- Start-up & site activation rescue
- Data-lock acceleration sprints
- Protocol amendment authoring
- Risk-based monitoring deploy
Personnel
& Governance
Managed teams with embedded governance, the most common rescue entry point. Full-functional or cross-functional team under our delivery oversight.
- FSP team deployment
- Full CRO oversight & metrics
- Client Delight COE active
- Stage-Gate G1–G5 governance
Operational Partnership
End-to-end study or program delivery, trial rescue from diagnosis through data-lock, submission-ready evidence, and close-out.
- Full trial turnaround ownership
- Portfolio-level PM-COE
- RWE/RWD COE standards
- Regulatory submission support
Strategic Partnership
Multi-program, multi-year, operating as the sponsor's extended clinical operations leadership with shared outcome accountability.
- Fractional CCO / Head of Ops
- Annual Operating Plan alignment
- Portfolio-wide delivery metrics
- Advisory & board-level support
Two processes. Five gates. Zero translation loss.
Our Business Acquisition Process (BAP) and Business Execution Process (BEP) run as paired systems: every commitment made in the bid phase is operationalized into execution without the handoff failure that kills most sponsor engagements.
BAP, Business Acquisition Process
Stage-gated commercial pipeline from first interest through contract. Turns sales from art into a repeatable system.
BEP, Business Execution Process
Execution counterpart to BAP. Every sales commitment is operationalized, with a seamless handoff from won to delivered.
5-Gate Stage-Gate Review System
Formal evaluation at every phase, risk surfaced early rather than at data lock. Matches management intensity to project complexity.
Strategy
Scope, fit, go/no-go
Planning
Protocol, budget, risk
Readiness
Sites, systems deployable
Excellence
Mid-study delivery
Close-Out
Data lock, CSR, sub
Four Center of Excellence models. Deployable into any sponsor environment.
Every engagement applies four Center of Excellence models the principal built and led in prior global roles, adopted across pharma, biotech, device, and academic sponsors.
Outsourced delivery,
sponsor-retained control.
Governance architecture used for 30+ international Phase I–IV trial rescues. The sponsor retains visibility, communication, and quality authority while Clinical TrialRx carries the execution load.
The "YES" system
, engineered, not aspirational.
Systematic approach combining Clinical-RWE Operations and Project Management across Phase I–IV, Late Phase, RWE, and Central Lab studies. Each of the 7 NOs in the VOC framework becomes a YES lever: governed, measured, and owned.
Submission-grade real-world evidence, not post-hoc.
Standards, training, and delivery across 20 countries. Systematic literature review and real-world data-lake strategies producing FDA, EMA, PMDA, TGA, and HSA-submissible evidence packs. Observational, registry, PASS, PRO, HEOR, and pragmatic Phase IV designs.
Project management, operationalized for clinical.
Four PM Centers of Excellence built across the Americas, EU, and APAC. Standardized processes, training, and earned-value metrics lift delivery efficiency and client satisfaction across 20 countries. Integrates with AI/ML-driven trial analytics.
Predictive Enrollment
ML models forecast site-level enrollment trajectories from screening, recruitment, and historical performance, flagging shortfalls before they reach the timeline.
Site Risk Scoring
Dynamic risk profiling across data quality, deviation rate, query velocity, and PI engagement, feeds the Risk-Based Monitoring queue automatically.
Monitoring Triage
Centralized monitoring algorithms surface anomalies in SDV, AE reporting, and protocol deviations, directing CRA effort to the sites that carry the most risk.
Signal Detection (PV)
Pharmacovigilance signal-detection models for safety and efficacy in post-market and RWE programs, surfacing trends early for safety review.
Data-Lake Generation
Real-world data-lake architecture ingesting claims, EHR, registry, and PRO data. Designed to produce FDA, EMA, and PMDA-submissible evidence packs.
Bid Scoring & VOC
ML-driven bid-defense win-rate modeling and Voice-of-Client diagnostic, flagging where sponsor relationships are at risk, with intervention pathways.
Build. Transfer. Exit.
You own the system in 18 months.
Many consulting engagements build and then stay. BTE is designed to exit. The Build-Transfer-Exit (BTE) Model architects an internal AI/ML clinical operations capability that your team owns and runs, with us out of the building by month 18. Built specifically for F500 pharma sponsors targeting 35% headcount efficiency without sacrificing pipeline velocity.
18-Month Pilot Build
Headcount Efficiency
Year 2 Forward
Build
Embedded senior operator plus AI/ML engineering team architect the data-lock orchestration platform. Integrate with sponsor's EDC, CTMS, Veeva Vault, and PV systems. Deploy live in pilot therapeutic area. Co-author governance with sponsor's Head of Clinical Operations.
- AI/ML model architecture + training
- System integration & pilot TA live
- Governance framework co-authored
- Quarterly board reviews initiated
Transfer
Sponsor team trained, certified, and progressively assumes operations. Side-by-side delivery becomes shadow delivery becomes hands-off. IP transferred under sponsor ownership. Internal champions identified and elevated to platform leadership.
- Sponsor team trained & certified
- Operations handed off by TA
- Full IP transferred to sponsor
- Internal champions in platform lead roles
Exit
Sponsor owns and runs the system end-to-end. We provide quarterly advisory only. Headcount efficiency results validated to the board, ROI measured, internal team fully autonomous. Clean exit with optional ongoing advisor retainer.
- Sponsor fully autonomous
- ROI validated to board
- Headcount results measured against plan
- Optional advisor retainer only
Molecule to approval.For emerging biotech leaders who cannot afford to get the first trial wrong.
For startup biotechs and emerging life science companies, we structure smaller, sharper engagements. Fractional clinical development leadership, pre-IND audits, project sprints, and board advisory. The same operator who has architected Phase I-IV programs across 30 countries and 22+ therapeutic areas, scaled to where you are.
Discovery & Preclinical
Clinical operations input to the IND-enabling plan, before the first dollar goes to tox.
- Clinical development plan input
- IND-enabling roadmap review
- Clinical operations readiness
- Preclinical-to-clinical CRO selection
IND / CTA Submission
The first regulatory file is also your first credibility statement to acquirers.
- Pre-IND meeting prep
- Clinical sections coordination
- Regulatory pathway analysis
- Multi-agency strategy
Phase I FIH
First-in-human is where startup discipline either compounds or unravels.
- Protocol & endpoint design
- Site & CRO selection
- Dose-escalation governance
- Safety review setup
Phase II POC
The proof-of-concept that triggers the next financing round or partnership.
- Adaptive trial design
- Biomarker strategy
- Interim analysis framework
- Investor & partner readouts
Phase III Pivotal
This trial is your company's valuation. The principal has directed an $875M, 10,101-patient Phase III program.
- Pivotal protocol architecture
- FSP / CRO governance
- Risk-based monitoring
- End-of-Phase II / SPA
BLA / NDA Submission
Submission readiness is decided long before the filing date.
- CTD module strategy
- Pre-NDA meeting prep
- Clinical operations readiness for submission
- FDA, EMA, PMDA coordination
Phase IV / Post-Market
Approval is the start, not the finish. RWE shapes label expansion and payer access.
- Post-marketing commitments
- REMS architecture
- Phase IIIb / IV design
- Pharmacovigilance setup
RWE / RWD Programs
Beyond the label: market access, payer dossiers, and the data engine behind them.
- RWE study design
- Data-lake architecture
- HEOR & payer evidence
- Registry & observational
Pick the shape that fits your stage and runway.
Pre-IND Strategic Audit
Independent assessment of your IND-enabling roadmap, clinical operations readiness, and regulatory pathway choice before you commit to a tox program or an agency meeting.
- IND-readiness scoring
- Regulatory pathway recommendation
- CRO / partner shortlist
- 12-month operational roadmap
Fractional Head of Clinical Development
The most common startup engagement. We embed as your fractional Head of Clinical Development or Head of Clinical Operations, sitting in your weekly clinical operations meetings, your partner conversations, and your board updates.
- Clinical operations leadership
- Regulatory strategy oversight
- Vendor & CRO governance
- Board & investor reporting
Targeted Project Delivery
Single-deliverable engagements for specific milestones. IND filing, pre-NDA prep, FSP architecture, Phase III protocol design, or an acquirer-readiness diligence audit.
- IND / CTA operational readiness
- Pivotal trial design
- FSP / CRO RFP & selection
- Acquirer diligence prep
Scientific & Clinical Advisory Board
Lighter-touch role for early-stage companies where the board needs a senior clinical operations voice but the trial work has not started. Often the first step before a fractional engagement.
- Board-level clinical advisor
- Quarterly strategic reviews
- Diligence call support
- Partner / investor warmup
Tell us where you are.We will tell you what we would do next.
Every operator call begins with a 30-minute conversation: where you are, what is coming, and the two or three operational decisions that will most shape the next 12 months. No deck and no pitch.
If we are a fit, we will propose a path. If we are not, we will tell you who is.
Seven capabilities, one accountable operator.
Sponsors often buy these as slices: a monitoring firm, an RWE shop, a bid-defense consultant, an AI/ML vendor. Clinical TrialRx delivers them as one architecture, under one operator with a documented delivery record at each level.
Every phase, plus RWE. 300+ protocols. 22+ therapeutic areas.
Clinical operations directed across every phase of the drug development lifecycle. The portfolio below reports aggregate totals by phase, the scale of trials the principal has been responsible for, not individual sponsor engagements.
Safety + PK/PD
Efficacy Signal
$875M Program
Long-Term Follow-Up
Every Phase
"Right the First Time, On-Time, On-Target."
What Clinical TrialRx delivers to every sponsor, so our clients Out-Pace in Their Space.
The metrics behind the methodology.
Every framework on this site was forged in delivery: global trials, F500 commercial mandates, start-up advisory work, and 30+ international rescues. The portfolio below summarizes the principal's documented career record.
Portfolio Totals
The Trial Portfolio
Clinical trial accountability across every phase, every geography, and every regulatory pathway, from concept through submission through post-market surveillance.
22+ Therapeutic Areas
Multi-indication depth spanning oncology, cardiovascular, CNS / neurology, rare disease, endocrine, immunology, infectious disease, hematology, ophthalmology, and more across the drug development lifecycle.
Revenue Growth · Commercial Leadership
Commercial results from separate senior roles: a company-record $302M in revenue growth over 19 months, $107M in new revenue from three partnerships, and PM-COE buildout across three continents.
Your trial is off-course.
We put it back on target.
Start with a no-obligation rescue assessment. We will diagnose where your program has drifted, map the VOC-7 failure modes actively dragging it, and show you a governed path to recovery in 30 minutes.
Pittsboro, IN 46167